TRACON Pharmaceuticals Inc (NASDAQ:TCON) said it has appointed Dr Lisa Johnson-Pratt to the company’s board of directors.
TRACON noted that Dr Johnson-Pratt brings more than two decades of broad business and commercialization leadership experience to the company and she currently serves as the senior vice president, New Product Planning at Ionis Pharmaceuticals, Inc.
“We are very pleased to welcome Lisa to TRACON’s Board of Directors. She is a physician who has focused the majority of her career on the commercialization of innovative products, including Gardasi and Singulairat Merck, prior to her appointment as Head of the Global Commercial Operations at GlaxoSmithKline PLC (GSK),” TRACON CEO Dr Charles Theuer said in a statement.
READ: TRACON Pharmaceuticals ends FY2020 with $36.1M in cash and equivalents
He added: “Her strong track record of successful strategic, operational and financial management, combined with her vast commercial experience will be invaluable to TRACON as we execute on our plan to complete clinical development and potentially commercialize envafolimab in the United States in 2023.”
Dr Johnson-Pratt commented: “TRACON has a first-class management team, an efficient platform to conduct global clinical trials, and a promising drug candidate with near-term commercial potential in envafolimab.”
“I am thrilled to support TRACON’s mission to commercialize envafolimab and address significant unmet needs in patients with cancer,” she added.
Dr Johnson-Pratt joined Ionis following its acquisition of Akcea Therapeutics, where she was an Executive Council member and led an integrated medical team responsible for the commercialization strategy of two novel late-stage antisense assets.
Before that, she was head of Global Pharma Commercial Operations at GSK. During her time there, she also served as head of Early Pipeline Commercial Strategy supporting assets in early-stage development across multiple therapeutic areas, including oncology.
TRACON has positioned itself as a collaboration partner that leads the regulatory filings, clinical trials, as well as US commercialization of best-in-class drug candidates, as an alternative to expensive contract research organization (CRO) based development.
Contact Sean at sean@proactiveinvestors.com